Business
Astellas and Taysha Gene Therapies Announce Strategic Investment to Support Development of Taysha's AAV-based Gene Therapy Programs
- Taysha Gene Therapies is an emerging leader in the development of AAV gene therapies; new collaboration aimed at enhancing development of two of Taysha's
About this update from Taysha Gene Therapies, Inc.
[{"type":"text","content":"- Taysha Gene Therapies is an emerging leader in the development of AAV gene therapies; new collaboration aimed at enhancing development of two of Taysha's novel product candidates for rare monogenic central nervous system diseases with serious unmet medical needs -\n- Astellas to invest a total of $50 million to acquire 15% of the company and to receive an exclusive option to obtain an exclusive license for TSHA-102 for Rett syndrome and TSHA-120 for giant axonal neuropathy (GAN) -\n- Astellas to receive certain rights related to any potential change of control of Taysha -\n- Astellas to receive one Board observer seat on the Taysha Board of Directors -\nTOKYO and DALLAS, Oct. 24, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., \"Astellas\") and Taysha Gene Therapies, Inc. (NASDAQ: TSHA, CEO: RA Session II, \"Taysha\") today announced a strategic investment to support the advancement of Taysha's adeno-associated virus (AAV) gene therapy development programs for the treatment of Rett syndrome and GAN. The future options to potentially apply Astellas' global R&D, manufacturing and commercialization capabilities in gene therapy to Taysha's innovative AAV gene therapy development programs for genetic diseases of the central nervous system (CNS) create the opportunity for the two companies to enhance the development of novel treatment options for patients with Rett syndrome and GAN, who have serious unmet medical needs.\n\n \n \n \n \n \n \n\n \nUnder the terms of the agreement, Astellas will invest a total of $50 million to acquire 15% of the outstanding common stock of Taysha and to receive an exclusive option to license two of Taysha's clinical stage programs: TSHA-102 for Rett syndrome and TSHA-120 for GAN. In addition, Taysha has granted Astellas certain rights related to any potential change of control of Taysha. Definitive agreements would be executed upon Astellas' exercise of any such option, and any change of control transaction would require approval by Taysha's stockholders.\nTaysha is engaged in the development of intrathecally-delivered AAV gene therapies for monogenic CNS diseases. As a part of this platform approach, Taysha has a promising pipeline, including TSHA-102, which is the first-and-only gene therapy in clinical development for Rett syndrome, and TSHA-120, whic...